BeiGene Ltd.

Amgen states no association between MariTide and bone mineral density changes, affirming its promise. Phase 2 data is expected later in 2024.

The article discusses the importance of enabling JavaScript for optimal app performance.

SpringWorks Therapeutics reports $49.3 million in OGSIVEO® (nirogacestat) net product revenue in Q3, with long-term Phase 3 DeFi trial data showing tumor size reduction and consistent safety. The FDA granted Priority Review for mirdametinib's NDA, and SpringWorks has $498 million in cash to fund operations through anticipated profitability in H1 2026.

Show Chwan Health Care System signs MOU with Novotech, a CRO, to enhance clinical trial capabilities in Changhua and Tainan. The partnership aims to bring the latest treatment technologies to doctors and patients, while ensuring subject protection through IRB and HRPC. Novotech, with over 5,000 trial projects and 34% in Phase I and II, will focus on clinical trial development and education.

Zymeworks Inc. initiates a Phase 1 trial to assess ZW191's safety and tolerability in treating advanced FRα-expressing solid tumors, including ovarian, endometrial, and NSCLC cancers. The global study aims to enroll 145 patients across North America, Europe, and the Asia-Pacific region.

BeiGene's CMO, Mark Lanasa, discusses the company's 'multiple shots on goal' approach to drug development, emphasizing early-stage clinical trials and in-house operations to reduce costs and time, aiming for more affordable innovation in cancer treatment.

Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.

CHMP recommends extended authorization for TEVIMBRA in gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma, based on RATIONALE-305 and 306 studies showing significant overall survival benefits.

China Merchants CSI Vaccine and Biotechnology ETF (561920) closed up 0.00% on Oct 21, with a turnover of 558,400 yuan. The fund, established on Mar 15, 2023, has seen a 19.61% decrease in shares and a 37.69% decrease in scale since the beginning of the year. Fund manager Hou Hao has managed the ETF since Jul 13, 2024, achieving a 14.80% return. The ETF's top holdings include Zhifei Biotech, Wantai Biotech, Watson Biotech, and others.